# CJC-1295 Dosage in the Research Literature > CJC-1295 dosage in published Phase I research: single subcutaneous doses of 30, 60, 125, and 250 µg/kg in the Teichman 2006 trial, alongside the compounding-pharmacy gray-literature protocols. _The Phase I ladder, the rodent characterization doses, the compounding-pharmacy protocols, and what each register can and cannot tell you._ ## The published Phase I ladder CJC-1295 dosage in the published research begins with one trial. Teichman 2006 administered single subcutaneous doses of 30, 60, 125, and 250 µg/kg of CJC-1295 with DAC to healthy adults in a Phase I dose-escalation design [1]. Across the four doses, mean plasma growth-hormone rose 2- to 10-fold in a dose-dependent fashion, and mean plasma IGF-1 rose 1.5- to 3-fold for nine to eleven days [1][2]. No subsequent human trial has expanded the dose range or characterized chronic-dose response in detail. Repeat-dose subgroups in the Teichman protocol — administered every one or two weeks — produced cumulative IGF-1 elevation that remained above baseline for up to twenty-eight days [2]. The Phase I record stops there. There is no Phase II dose-finding study in any indication that has been published in the peer-reviewed literature beyond the halted 2006 ConjuChem HIV-lipodystrophy trial, for which detailed dose information was not made public [13]. ## Doses used in published research ### Doses used in published research Phase I human trials used 30, 60, 125, and 250 µg/kg single subcutaneous doses (Teichman 2006) [1]. Rodent receptor-characterization studies used low-microgram intravenous or subcutaneous boluses (Jetté 2005) [4]. GHRH-knockout mouse rescue used once-daily subcutaneous DAC variant (Alba 2006) [5]. Compounding-pharmacy protocols cited in the gray literature run 100-300 µg total daily for the no-DAC variant and weekly 1-2 mg for the DAC variant — these are protocol claims, not research-validated regimens [12]. ## Administration in research settings ### Administration in research settings Subcutaneous injection in all published human trials [1]. Rodent studies used both subcutaneous and intraperitoneal routes; the foundational Jetté 2005 receptor work also used intravenous administration in rats to characterize the albumin-bioconjugate pharmacokinetics directly [4]. The lyophilized peptide is reconstituted with bacteriostatic water in research handling; specific reconstitution volumes depend on vial mass and the intended concentration of the working solution. ## Dosing frequency ### Dosing frequency With DAC: weekly in the Phase I trial, supported by the multi-day half-life [1][2]. Without DAC (modified GRF 1-29): gray-literature protocols dose one to three times daily because the half-life is approximately thirty minutes and any sustained GH-axis effect requires repeated stimulation [12]. The biological rhythm reflects the molecule: the DAC variant raises the GH baseline; the no-DAC variant produces brief pulses. ## Reconstitution in published protocols ### Reconstitution in published protocols Lyophilized peptide is reconstituted with bacteriostatic water in research settings. Specific volumes depend on the vial mass and intended concentration; this is laboratory handling, not a clinical prescription. The Phase I record (Teichman 2006) does not publish a reconstitution SOP because reconstitution is upstream of trial administration — it is the standard handling of a lyophilized injectable peptide and not part of the dosing endpoint itself [1]. ## The compounding-pharmacy literature, marked as gray Compounding-pharmacy dosing protocols for CJC-1295 — typically the no-DAC variant or 'CJC-1295 + ipamorelin' formulations — circulate widely in clinic marketing, compounding-pharmacy product sheets, and direct-to-consumer education. Common citations include 100-300 µg total daily for the no-DAC variant (split into one to three injections) and 1-2 mg weekly for the DAC variant [12]. These are not research-validated regimens. They are protocol claims, generated and circulated within the compounding-pharmacy ecosystem, and not derived from any published trial. The peer-reviewed Phase I doses (30, 60, 125, 250 µg/kg) and the compounding-pharmacy daily-total figures occupy different epistemic registers and should not be conflated. On this page they are rendered in different rules to make the distinction visible at a glance. ## What the research-dose record does not say The published Phase I literature does not say what dose is 'effective' for body composition, anti-aging, sleep, recovery, or any clinical endpoint. It says what dose produces what pharmacodynamic effect on mean plasma GH and IGF-1 in healthy adults [1][2]. Clinical dose-finding belongs to Phase II and III work that has not been completed for CJC-1295. The pharmacy dossier renders the doses that exist; it does not invent the doses that do not. The reader who wants a clinical dose recommendation will not find one here because none exists in the public record. ## References [1] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/ [2] Teichman SL, et al. CJC-1295 Phase I pharmacokinetics — half-life and IGF-1 elevation duration data. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/ [4] Jetté L, et al. CJC-1295 albumin-conjugation pharmacokinetics in rats — peptide detectable in plasma beyond 72 hours, 4-fold GH AUC over unmodified GRF. Endocrinology. 2005;146(7):3052-3058. https://pubmed.ncbi.nlm.nih.gov/15817669/ [5] Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. https://pubmed.ncbi.nlm.nih.gov/16822960/ [12] Modified GRF (1-29) — chemistry and pharmacology overview (review compendium, citing primary GRF analog literature). https://en.wikipedia.org/wiki/Modified_GRF_(1-29) [13] Aidsmap editorial. Lipodystrophy study halted after patient death (news report on ConjuChem Phase II CJC-1295 trial). aidsmap.com. 2006. https://www.aidsmap.com/news/jul-2006/lipodystrophy-study-halted-after-patient-death --- A compounding-pharmacy reading room for the CJC-1295 research record — Phase I evidence rendered in solid rules, gray-literature claims in dashed ones, no scripts filled on the premises.